BioCryst Pharmaceuticals (NASDAQ: BCRX) was on the move Tuesday after inking letters of intent with three partners, who will take the lead on stockpiling, marketing, and distribution efforts for the company's influenza treatment in four countries. Marketing and distribution will be contingent upon local regulatory approval, but all three partners will immediately begin discussing stockpiling opportunities with the appropriate government officials.
Moksha8 Pharmaceuticals will be BioCryst's representative in Brazil and Mexico, which together account for 75% of the Latin American pharmaceutical market. Meanwhile, NT Pharma Co. is the company's Chinese partner, and Neopharm Group is taking the reins in Israel.